Navigation Links
Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
Date:10/11/2007

Dr. Daniel Weiner Will Discuss Challenges and Opportunities to Realize

Critical Path Initiative Goals

MOUNTAIN VIEW, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Daniel Weiner, Ph.D., senior vice president and chief technology officer, has been invited to speak to U.S. and Japanese biopharmaceutical executives attending a session on research and development productivity hosted by the New York Pharma Forum (NYPF), to be held in New York City, October 15, 2007.

Dr. Weiner's presentation will discuss the technical, organizational and process changes needed to reach the goals of the FDA's Critical Path Initiative for improving drug development productivity, including opportunities for the adoption of quantitative drug-disease modeling and simulation. Dr. Weiner will join other industry experts as part of the NYPF program entitled "R&D Productivity: Are There Winning Strategies?" The session will also offer a forum for interdisciplinary discussion on areas of opportunity in the drug development and approval process.

"Pharsight has built a strong reputation for providing critical solutions that increase productivity in the drug development industry," said Shawn O'Connor, president, chief executive officer, and chairman of Pharsight. "Through our strategic consulting services and growing family of software products, we have successfully collaborated with global drug developers to incorporate modeling and simulation into their development processes. These collaborations have yielded a number of success stories, ranging from increased efficiencies and more confident decision-making to better resource management. Pharsight is pleased to participate at this NYPF event, and to offer its perspectives on opportunities, challenges and supporting technical infrastructure to enable critical path clinical research in Japan and globally."

The New York Pharma Forum is a non-profit organization that provides U.S. and Japanese biopharmaceutical company executives with access to critical information on business, policy and technology issues that impact the global healthcare industry, with a focus on Japan. Additional information can be found at http://www.nypharmaforum.org.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Forward Looking Statements

The statements in this press release related to the performance and benefits of Pharsight products and services are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations and customers may not perceive the benefits of Pharsight software products and services to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-Q filed with the Securities and Exchange Commission on August 13, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trade marks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Why companies dont get invited to the DEMO conference
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- In Atlanta, it seems everyone has a chance to express ... an expressive and dynamic community unlike any other. The businesses ... it. With their newest salon in ... carry on that tradition with a unique, fresh approach to ... is the newest of 13 nationwide locations, each of them ...
(Date:2/23/2017)... TX (PRWEB) , ... February 23, 2017 , ... ... Administration (FDA) de novo clearance to begin marketing the SPEAC® System, the Brain ... for adults at home or in healthcare facilities during periods of rest. A ...
(Date:2/23/2017)... ... 2017 , ... Today, researchers can fast-track sample collection and ... other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With the ... between insulin and other relevant biomarkers can be extensively studied through a non-invasive ...
(Date:2/23/2017)... Aviva Systems Biology Corporation (ASB) which ... GenWay Biotech Incorporated, a protein solutions and applications ... for both the research and diagnostic markets. ... capabilities for both entities. GenWay,s 18 years of experience ... complement ASB,s objective to become a leading provider ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
(Date:2/3/2017)... 2017  Texas Biomedical Research Institute announced that its Board ... as the Institute,s new President and CEO. Dr. Schlesinger ... 2017. He is currently the Chair of the Department of ... Microbial Interface Biology at Ohio State University. "We ... and CEO of Texas Biomed," said Dr. James O. ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent ... availability of a new report, Sensors for Robotics: Technologies, Markets ... ... ... IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine ...
Breaking Biology News(10 mins):